SHIBATA Masami | Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
スポンサーリンク
概要
- 同名の論文著者
- Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers の論文著者
関連著者
-
SHIBATA Masami
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
Shibata Masami
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
SAGAMI Fumio
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
Sagami Fumio
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Kimura Juki
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
KADOTA TOSHIHITO
Non-Clinical Evaluation Subcommittee, Drug Evaluation, Japan Pharmaceutical Manufacturers Associatio
-
Saito Akemi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
NAGAYAMA Takashi
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
SHIBATA Akiko
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
TANIGUCHI Katsuhiko
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
MATSUZAWA Toshiaki
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
Kido Toshihito
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Kadota Toshihito
Non-clinical Evaluation Subcommittee Drug Evaluation Japan Pharmaceutical Manufacturers Association
-
Shibata Akiko
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Matsuzawa Toshiaki
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Matsuzawa Toshiaki
Non-clinical Evaluation Subcommittee Drug Evaluation Japan Pharmaceutical Manufacturers Association
-
Matsuzawa Toshiaki
Non-clinical Evaluation Subcommittee Drug Evaluation Japan Pharmaceutical Manufacturers Association
-
Taniguchi Katsuhiko
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Nagayama Takashi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Matsuzawa Toshiaki
Non-clinical Evaluation Subcommittee Drug Evaluation Japan Pharmaceutical Manufacturers Association
-
NAGAYAMA Takashi
Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association
-
KIDO Akihiko
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
Kido Akihiko
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
KIDO Toshihito
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers
-
Nomura Akio
Non-clinical Evaluation Subcommittee Japan Pharmaceutical Manufacturers Association (jpma):santen Ph
-
Unno Takashi
Non-clinical Evaluation Subcommittee Japan Pharmaceutical Manufacturers Association (jpma):nippon Or
-
Shibata Masami
Non-clinical Evaluation Subcommittee Japan Pharmaceutical Manufacturers Association (jpma):nikken Ch
著作論文
- O-09 No-Observed Adverse Effect Level(NOAEL) : Judging Criteria and Purpose in Safety Assessment of Pharmaceuticals(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-08 Questionnaire Survey on No Observed Adverse Effect Level(2) : Regulatory Comments and Company(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-07 Questionnaire Survey on No Observed Adverse Effect Level(1) : Concept of NOAEL(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Points to Consider for Safety Pharmacology and Exposure Assessment on Biotechnology-Derived Pharmaceuticals.(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF NON-CLINICAL STUDIES ON BIO-PHARMACEUTICALS(CURENT SURVEY))